These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34718595)

  • 1. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
    Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Lee MH; Li HJ; Wasuwanich P; Kim SE; Kim JY; Jeong GH; Park S; Yang JW; Kim MS; Yon DK; Lee SW; Koyanagi A; Jacob L; Kim EY; Cheon JH; Shin JI; Smith L
    Rev Med Virol; 2023 Mar; 33(2):e2414. PubMed ID: 36504172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.
    Alrashed F; Battat R; Abdullah I; Charabaty A; Shehab M
    BMJ Open Gastroenterol; 2021 Oct; 8(1):. PubMed ID: 34725056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
    Chen L; Hu K; Cheng C; Hu Q; Zhang L; An T; Guo Y; Chen S; Duan G
    Int J Colorectal Dis; 2022 Nov; 37(11):2277-2289. PubMed ID: 36271206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease.
    Long MD; Parlett L; Lewis JD; Haynes K; Adimadhyam S; Hou L; Wolfe A; Toh S; Burris J; Dorand J; Kappelman MD
    Inflamm Bowel Dis; 2024 Aug; 30(8):1345-1352. PubMed ID: 37611117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
    D'Amico F; Danese S; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2689-2700. PubMed ID: 32777550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
    Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
    Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and associated factors of hair loss among patients with inflammatory bowel disease.
    Shah R; Abraham B; Hou J; Sellin J
    World J Gastroenterol; 2015 Jan; 21(1):229-32. PubMed ID: 25574095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.
    Rozich JJ; Dulai PS; Fumery M; Sandborn WJ; Singh S
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2437-2447.e6. PubMed ID: 32142940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Moosvi Z; Duong J; Bechtold ML; Nguyen DL
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):799-816. PubMed ID: 33079779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.
    Kjeldsen S; Nielsen J; Mertz Nørgård B; Kjeldsen J
    Inflamm Bowel Dis; 2022 Oct; 28(10):1513-1519. PubMed ID: 34849917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Singh AK; Jena A; Kumar-M P; Sharma V; Sebastian S
    United European Gastroenterol J; 2021 Mar; 9(2):159-176. PubMed ID: 33210980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.